Review of 20-year results of ASCOT Legacy
https://doi.org/10.15829/1560-4071-2023-5457
Abstract
The article presents the results of a 20-year follow-up of patients in the ASCOT Legacy study, indicating that antihypertensive and lipid-lowering therapy reduces mortality in patients with hypertension and high cardiovascular risk in the long term. In the group of patients treated with amlodipine compared with the β-blocker atenolol, there was a decrease in mean systolic and diastolic blood pressure (BP), as well as a long-term improve in the form of a decrease in the prevalence of cardiovascular events and mortality due to stroke. An important feature of therapy based on amlodipine was the reduction in BP variability. The article reflects the results of major studies that determine the possibility and effectiveness of early prescription of combined antihypertensive and lipid-lowering therapy.
About the Authors
M. B. Nagorny
S. M. Kirov Military Medical Academy
Russian Federation
Russian Federation
St. Petersburg
A. N. Kuchmin
S. M. Kirov Military Medical Academy
Russian Federation
Russian Federation
St. Petersburg
References
1. World Health Organization. Global Health Estimates 2015: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2015. Evidence and Research (2016).
2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-80. doi:10.1016/S0140-6736(21)01330-1.
3. Teo KK, Rafiq T. Cardiovascular Risk Factors and Prevention: A Perspective From Developing Countries. Canadian Journal of Cardiology. 2021;37(5):733-43. doi:10.1016/j.cjca.2021.02.0094.
4. Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.
5. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an anti¬hypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. doi:10.1016/S0140-6736(05)67185-1.
6. Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomized factorial trial. Lancet. 2018;392(10153):1127-37. doi:10.1016/S0140-6736(18)31776-8.
7. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihyper¬tensive and lipid-lowering therapy. Arch. Intern. Med. 2005;165(10):1147-52. doi:10.1001/archinte.165.10.1147.
8. ASCOT Legacy: Long-Term Benefits of BP, Cholesterol Management on HTN Aug 26, 2018 ACC News Story. https://www.acc.org/latest-in-cardiology/articles/2018/08/20/17/59/sun-5am-ascot-esc-2018.
9. Sever P, Gupta A, Whiteley W, et al. S-28-8: The ASCOT LEGACY cohort: the long-term effects of blood pressure and blood pressure variability on cardiovascular and renal outcomes. Journal of Hypertension. 2023;41,e-Supplement 1,e67-e68. doi:10.1097/01.hjh.0000913376.59859.51.
10. Gupta A, Whiteley W, Godec T, et al. The relationship between BP-control, BP-variability and antihypertensive treatment with the longterm risk of cardiovascular event: lessons from the ASCOT-LEGACY 20-year follow-up, Journal of Hypertension. 2021;39:e148. doi:10.1097/01.hjh.0000745996.70900.76.
11. Gupta A, Whiteley W, Godec T, et al. Long term benefits of blood pressure treatment on the incidence of atrial fibrillation, heart failure and cardiovascular morbidity and mortality: 20-years follow-up of ASCOT-LEGACY. Journal of Hypertension. 2021;39:e8. doi:10.1097/01.hjh.0000744436.51700.9f42.
12. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-25. doi:10.1161/CIRCULATIONAHA.105.595496.
13. Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension. 2018;7(4):846-53. doi:10.1161/HYPERTENSIONAHA.118.11308.
14. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-57. doi:10.1161/HYPERTENSIONAHA.120.15026.
15. Bangalore S, Kumar S, Messerli FH, et al. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians’ Desk Reference. Am. J. Med. 2010;123(11):1016-30. doi:10.1016/j.amjmed.2010.06.014.
16. Arnold JM, Yusuf S, Young J, et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003;107(9):1284-90. doi:10.1161/01.cir.0000054165.93055.42.
17. Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc. Res. 2007;73(1):237-46. doi:10.1016/j.cardiores.2006.10.021.
18. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-41. doi:10.1016/S0140-6736(01)06178-5.
19. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217-25. doi:10.1001/jama.292.18.2217.
20. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 2004;351(20):2058-68. doi:10.1056/NEJMoa042739.
21. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008;358(15):1547-59. doi:10.1056/NEJMoa0801317.
22. Wei J, Galaviz KI, Kowalski AJ, et al. Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis. JAMA Netw. Open. 2020;3(2):e1921618. doi:10.1001/jamanetworkopen.2019.21618.
23. Kim YH, Her A-Y, Jeong MH, et al. Comparison of clinical outcomes between angio¬-tensin-converting-enzyme inhibitors and ARBs in patients with acute myocardial infarction with dyslipidemia after a successful stent implantation. Anatol. J. Cardiol. 2020;23(2):86-98. doi:10.14744/AnatolJCardiol.2019.60374.
24. Karpov YuA, Deev AD. Uncontrolled arterial hypertension — new opportunities in solving the problem of improving the effectiveness of treatment. Kardiologiia. 2012;2:29-35. (In Russ.)
25. Karpov YuA, Sorokin EV. The effect of combined hypotensive therapy on the risk of car¬diovascular complications and vascular age: the results of a multicenter open study of ADVANTAGE’AGE. Atmosphere. Cardiology news. 2015;3:2-10. (In Russ.)
26. Nedogoda SV, Konradi AO, Zvartau NE, et al. Optimization of blood pressure control and angioprotection using a fixed combination of perindopril and amlodipine in patients with arterial hypertension and high pulse wave propagation velocity. Kardiologiia. 2017;57(3):31-8. (In Russ.)
27. Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398(10306):1133-46. doi:10.1016/S0140-6736(21)01827-4.
28. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am. J. Med. 2012;125(9):882-7. doi:10.1016/j.amjmed.2011.12.013.
29. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur. Heart J. 2013;34(38):2940-8. doi:10.1093/eurheartj/eht295.
30. Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) doi:10.15829/29/1560-4071-2020-4076.
31. Jacob S, Weger B. Blood pressure, lipid lowering and self-reported adherence with a fixed-dose combinaton of Atorvastatin/Perindopril/Amlodipine in primary care: a non-interventional study. Der Internist. 2018;59(1):PS157. doi:10.1097/01.HJH.0000523313.46927.8F.
32. Simon A, Dezsi CA. Treatment of hypertensive and hypercholesterolaemic patients with the triple fixed combination of atorvastatin, perindopril and amlodipine: the results of the CORAL study. Adv. Ther. 2019;36(8):2010-20. doi:10.1007/s12325-019-01002-8.
33. Dezsi СА. Treatment with triple combination of atorvastatin, perindopril, and amlodipine in patients with stable coronary artery disease: a subgroup analysis from the PAPA-CAD study. J. Int. Med. Res. 2018;46(5):1902-9. doi:10.1177/0300060518760158.
Review
For citations:
Nagorny M.B., Kuchmin A.N. Review of 20-year results of ASCOT Legacy. Russian Journal of Cardiology. 2023;28(5):5457. (In Russ.) https://doi.org/10.15829/1560-4071-2023-5457
Views:
987
Email this article 